Home > Insider Trading > Filing (0001418812-14-000081)

Filing Details

Accession Number:: 0001418812-14-000081
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-11-26 16:11:41
Reporting Period:: 2014-11-24

Filing Date:: 2014-11-26
Accepted Time:: 2014-11-26 16:11:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
885590	Valeant Pharmaceuticals International Inc.	VRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1159187	W Jeffrey Ubben	One Letterman Drive Building D, 4Th Floor San Francisco CA 94129	Yes	No	No	Yes
1351069	Valueact Capital Management, L.p.	One Letterman Drive Building D, 4Th Floor San Francisco CA 94129	Yes	No	No	Yes
1351073	Valueact Capital Management, Llc	One Letterman Drive Building D, 4Th Floor San Francisco CA 94129	Yes	No	No	Yes
1418812	Va Partners I, Llc	One Letterman Drive Building D, 4Th Floor San Francisco CA 94129	Yes	No	No	Yes
1418813	Valueact Holdings Gp, Llc	One Letterman Drive Building D, 4Th Floor San Francisco CA 94129	Yes	No	No	Yes
1418814	Valueact Holdings, L.p.	One Letterman Drive Building D, 4Th Floor San Francisco CA 94129	Yes	No	No	Yes
1464912	Valueact Capital Master Fund, L.p.	One Letterman Drive Building D, 4Th Floor San Francisco CA 94129	Yes	No	No	Yes
1579734	Valueact Co-Invest Master Fund, L.p.	One Letterman Drive Building D, 4Th Floor San Francisco CA 94129	Yes	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, No Par Value	Acquisiton	2014-11-24	210,000	$142.25	17,780,936	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, No Par Value	1,352,941	Indirect	See footnotes

Footnotes

Each reporting person listed herein disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
The securities reported herein are directly beneficially owned by ValueAct Capital Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P. , (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P. , (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P. Jeffrey W. Ubben is a member of the management board of ValueAct Holdings GP, LLC.
The securities reported herein are directly beneficially owned by ValueAct Co-Invest Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) VA Partners I, LLC as General Partner of ValueAct Co-Invest Master Fund, L.P. , (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Co-Invest Master Fund, L.P. , (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P. Jeffrey W. Ubben is a member of the management board of ValueAct Holdings GP, LLC.